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SUMMARY 
Clavulanic acid and avibactam are clinically deployed serine ȕ-lactamase inhibitors, 
important as a defence against antibacterial resistance. Bicyclic boronates are recently 
discovered inhibitors of serine and some metallo ȕ-lactamases. Here we show that 
avibactam and a bicyclic boronate inhibit L2 (serine ȕ-lactamase) but not L1 (metallo ȕ-
lactamase) from the extensively drug resistant human pathogen Stenotrophomonas 
maltophilia. X-ray crystallography revealed that both inhibitors bind L2 by covalent 
attachment to the nucleophilic serine. Both inhibitors reverse ceftazidime resistance in 
S. maltophilia because, unlike clavulanic acid, they do not induce L1 production. 
Ceftazidime/inhibitor resistant mutants hyper-produce L1, but retain 
aztreonam/inhibitor susceptibility because aztreonam is not an L1 substrate. 
Importantly, avibactam, but not the bicyclic boronate  is deactivated by L1 at a low 
rate; the utility of avibactam might be compromised by mutations that increase this 
deactivation rate. These data rationalize the observed clinical efficacy of 
ceftazidime/avibactam plus aztreonam as combination therapy for S. maltophilia 
infections and confirm that aztreonam-OLNH ȕ-lactams plus non-classical ȕ-lactamase 
inhibitors, particularly avibactam-like and bicyclic boronate compounds, have potential 
for treating infections caused by this most intractable of drug resistant pathogens. 
  
This article is protected by copyright. All rights reserved.
3 
 
ABBREVIATED SUMMARY 
Stenotrophomonas maltophilia is an important bacterial pathogen that causes severe 
LQIHFWLRQV ,W FDQ EHFRPH UHVLVWDQW WR DOO ȕ-lactam antibacterials via mutations that 
HQKDQFH / DQG / ȕ-lactamase production. Characterisation of the interactions 
EHWZHHQ YDULRXV ȕ-lactamase inhibitors and L1 and L2, whole cell susceptibility tests 
and proteomic analysis of resistant mutants show that the monobactam aztreonam plus 
the non-ȕ-ODFWDP EDVHG ȕ-lactamase inhibitors avibactam and a novel cyclic boronate 
are excellent combinations against S. maltophilia. 
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INTRODUCTION 
ȕ-/DFWDPDVHV DUH WKH PRVW FRPPRQO\ HQFRXQWHUHG FDXVH RI UHVLVWDQFH WR ȕ-lactams, which 
are the most frequently prescribed class of antibacterial drug world-wide (Hamad, 2010, Van 
Boeckel et al., Versporten et al., 2014). ȕ-/DFWDPDVHV UHQGHU ȕ-lactams inactive through 
catalysing efficient hydrolysis of WKH ȕ-lactam ring (Strynadka et al., 1992, Drawz & 
Bonomo, 2010). There are many hundreds of known ȕ-lactamases, which are grouped based 
on sequence and mechanism into WKHVHULQHȕ-lactamase (SBL) classes A, C and D, and the 
metallo-ȕ-lactamase (MBL) subclasses B1, B2 and B3) (Ambler, 1980, Bush, 2013). Broad-
spectrum, cOLQLFDOO\ XVHIXO ȕ-lactamase inhibitors are being sought, but the varying 
chemistries and active site architectures of the different ȕ-lactamase classes makes the 
development of cross-class inhibitors extremely challenging (King et al., 2016, Brem et al., 
2016, Drawz et al., 2014). 
Clavulanic acid (Fig. 1, top) is a well-established clinically deployed ȕ-lactam-based 
inhibitor of, principally, class A SBLs. Clavulanic acid is used in combination with penicillin 
derivatives such as amoxicillin and ticarcillin, whose bactericidal effects improve against 
some ȕ-lactamase-carrying isolates of species such as Escherichia coli and Klebsiella 
pneumoniae (Al Roomi et al., 1984, Reading & Cole, 1977, Fass & Prior, 1989, Finlay et al., 
2003). Clavulanic acid is an irreversible inhibitor of class A enzymes, whose activity arises 
from fragmentation of the acyl-enzyme complex formed by reaction with the active-site 
serine nucleophile, to generate a near permanently inactivated species (Sulton et al., 2005). In 
contrast, avibactam, a recently introduced relatively broad spectrum non-ȕ-lactam-based SBL 
inhibitor contains a diazobicyclo heterocyclic core structure which reversibly acylates SBLs. 
The potency of avibactam against class A, C and some class D SBLs is attributed to the 
stabilization of the carbamoyl complex due to interactions with polar residues present in the 
active sites, with de-acylation preferentially occurring due to recyclization rather than 
This article is protected by copyright. All rights reserved.
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hydrolytic turnover (Ehmann et al., 2012). This recyclization results in release of intact active 
inhibitor rather than an inactive hydrolysis product (Fig. 1, middle) (Stachyra et al., 2010, 
Coleman, 2011, Wang et al., 2016, Choi et al., 2016). Avibactam has recently been licenced 
for clinical use in partnership with the oxy-amino cephalosporin ceftazidime, though the 
combination is not universally efficacious and has no useful activity against MBL-producing 
bacteria (Coleman, 2011, Abboud et al., 2016).  
Boronic acid-based compounds have long been studied as potential SBL inhibitors 
but, in most cases, are ineffective against MBL targets. For example, the monocyclic 
boronate vaborbactam (RPX7009) (Fig. 1, bottom left), which has recently been approved for 
clinical use, is effective against Class A, C and D ȕ-lactamases, but not MBLs (Hecker et al., 
2015). However, we recently demonstrated that bicyclic boronate scaffolds can act as potent 
inhibitors of multiple SBL classes, as well as subclass B1 MBLs (Brem et al., 2016). 
Accordingly, one method of overcoming the poor activity of ceftazidime/avibactam against 
MBL producing bacteria would be to combine ceftazidime with a bicyclic boronate inhibitor, 
such as 2 (Fig. 1, bottom right), or 1, which is derived from the same scaffold (Cahill et al., 
2017). Together, 1 and 2 represent the closest approach to a pan-ȕ-lactamase inhibitor that 
has, to-date, been reported in the literature (Cahill et al., 2017). Another bicyclic boronate ȕ-
lactamase inhibitor (VNRX-5133) has recently completed phase 1 clinical trials 
(ClinicalTrials.gov, 2016). 
Stenotrophomonas maltophilia (Ryan et al., 2009) is one of the most intrinsically 
multidrug resistant bacterial species encountered in the clinic, causing up to 5% of ventilator 
associated pneumonias, and around 1% of blood-stream infections. It causes serious 
infections with high mortality rates in immunocompromised and severely debilitated patients, 
and colonises the lungs of 20-30% of patients with cystic fibrosis (Brooke, 2012, de 
Vrankrijker et al., 2010, Looney et al., 2009). While S. maltophilia possesses multiple efflux 
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systems (Alonso & Martinez, 2000, Gould & Avison, 2006, Garcia-Leon et al., 2015, Gould 
et al., 2013) that reduce the net rate of entry for many antimicrobials, ȕ-lactam resistance 
arises primarily from production of WZR ȕ-lactamases, a subclass B3 MBL ³L1´, which 
hydrolyses all ȕ-lactams except for the monobactam, aztreonam, and the class A Extended 
Spectrum SBL (ESBL) ³L2´, which hydrolyses all first to third generation cephalosporins, all 
penicillins, and aztreonam (Walsh et al., 1994, Walsh et al., 1997, Gould et al., 2006). The 
combination of L1 and L2, therefore renders S. maltophilia resistDQW WR DOO ȕ-lactam 
antibiotics although in clinical practice, ceftazidime can be useful, because most clinical 
LVRODWHVGRQRWSURGXFHHQRXJKȕ-lactamase to give resistance (Lemmen et al., 2001, Okazaki 
& Avison, 2008). Ceftazidime resistant mutants rapidly emerge through hyper-production of 
L1 and L2, via single site mutations that directly or indirectly activate the L1/L2 
transcriptional activator, AmpR (Okazaki & Avison, 2008, Talfan et al., 2013). Accordingly, 
S. maltophilia UHSUHVHQWV RQH RI WKH PRVW FKDOOHQJLQJ WDUJHWV IRU ȕ-ODFWDPȕ-lactamase 
inhibitor combinations.  
Here we report kinetic and structural studies with purified S. maltophilia ȕ-
ODFWDPDVHV LQ YLWUR WHVWLQJ RI YDULRXV ȕ-ODFWDPȕ-lactamase inhibitor combinations against 
extensively drug resistant clinical S. maltophilia isolates, and characterisation of acquired 
resistance to these combinations. The results reveal that non-classical ȕ-lactamase inhibitors 
such as avibactam and bicyclic boronates have FRQVLGHUDEOHSRWHQWLDOLQFRPEDWWLQJȕ-lactam 
resistance in S. maltophilia, particularly when used in combination with aztreonam-like ȕ-
lactams. 
 
RESULTS 
ȕ-lactamase inhibitors restore aztreonam, but not meropenem activity against S. 
maltophilia  
This article is protected by copyright. All rights reserved.
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As a prelude to investigating WKH HIIHFWV RI ȕ-lactamase inhibitors, we first evaluated the 
K\GURO\VLVRIDUDQJHRIFDQGLGDWHȕ-lactams in vitro by purified L1 (subclass B3 MBL) and 
L2 (class A ESBL) under steady state conditions. These data (Table 1) reveal the 
carbapenem meropenem to be predominantly a substrate for L1, with L2 showing only weak 
hydrolytic activity, the monobactam aztreonam to be a substrate for L2 only, and that both L1 
and L2 can hydrolyse the oxyamino-cephalosporin ceftazidime with similar efficiencies. 
We next tested the ability of three ȕ-lactamase inhibitors: clavulanic acid, avibactam 
and the bicyclic boronate 2 (each at 2 mg.L-1) to potentiate the activity of the target ȕ-lactams 
against S. maltophilia (Table 2) All three inhibitors reversed aztreonam, but not meropenem 
resistance in ceftazidime susceptible clinical isolates (K279a, CI-20, CI-29). Furthermore, all 
three inhibitors reversed ceftazidime and aztreonam, but not meropenem, resistance in a 
ceftazidime-resistant L1/L2 hyper-producing mutant (K CAZ 10), derived from K279a 
(Table 2) (Talfan et al., 2013)). Interestingly, all three inhibitors were unable to restore 
ceftazidime susceptibility in a ceftazidime resistant L1/L2 hyper-producing clinical isolate 
(CI-31), but they all restored aztreonam resistance in CI-31 (Table 2).  
Efflux pumps play a major role in antimicrobial resistance in S. maltophilia 
(Crossman et al., 2008, Brooke, 2012). Thus, to investigate the possible effect of multi-drug 
HIIOX[SXPSVRQȕ-lactamase inhibitor efficacy, we selected two hyper-resistant mutants from 
the isolate K279a using moxifloxacin and amikacin, known to be efflux pump substrates. 
Comparative proteomics (Tables S1, S2, Fig. S1) confirmed that the two mutants, K MOX 8 
and K AMI 32, hyper-produce the SmeDEF and SmeYZ efflux pumps, respectively. In K 
MOX 8, SmeYZ was downregulated as SmeDEF was hyper-produced, as expected given 
their reciprocal regulation (Huang et al., 2017). All three ȕ-lactamase inhibitors retained full 
activity against these efflux pump hyper-producing mutants (Table 2) suggesting that efflux 
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does not have a major role in WKHREVHUYHGYDULDWLRQ LQ HIILFDF\RI WKHYDULRXVȕ-lactamȕ-
lactamase inhibitor combinations. 
 
The bicyclic boronate 2 does not inhibit the S. maltophilia L1 MBL 
Based on these in vitro data we conclude that the bicyclic boronate 2 acts against S. 
maltophilia in a similar fashion to avibactam and clavulanic acid: it reverses aztreonam 
and, when due to L1/L2 hyper-production, ceftazidime resistance (Table 2). As 2 has been 
shown to inhibit multiple MBLs (Brem et al., 2016), we anticipated that it might also 
inhibit L1, but the fact that 2 does not reverse resistance to meropenem (Table 2), which is 
predominantly hydrolysed by L1 (Table 1) suggests that L1 inhibition by 2 does not occur 
to a significant extent.  
As, to date, the inhibition of subclass B3 MBLs by bicyclic boronates has not been 
reported, we investigated the inhibition of purified L1 and L2 by the three ȕ-lactamase 
inhibitors using the IOXRURJHQLFȕ-lactamase substrate FC5 as a new reporter for L1 and 
L2(van Berkel et al., 2013). Calculated kcat/KM values clearly demonstrate that FC5 is 
hydrolysed with a higher efficiency WKDQ RWKHU ȕ-lactams by both L1 and L2 (Table 1). 
IC50 measurements revealed that while all three ȕ-lactamase inhibitors inhibit L2 with 
nanomolar potencies (Table 3), no inhibition of L1 was observed, even when using 
inhibitor concentrations up to 2.5 mM. NMR spectroscopy confirmed that there is no 
impact of avibactam or 2 on meropenem hydrolysis by L1 (Fig S2).  NMR experiments 
also showed that L1 can hydrolyse avibactam, albeit at a slow rate, but it does not modify 2 to 
any detectable extent following incubation up to 24 h (Fig. S3). Thus, unlike the case for 
subclass B1 MBLs (Brem et al., 2016), the bicyclic boronate 2 is not an effective inhibitor 
of the subclass B3 MBL L1. 
This article is protected by copyright. All rights reserved.
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Structural basis for inhibition of L2 by avibactam and the bicyclic boronate 2 
TKHUHVXOWVDERYHGHPRQVWUDWHWKDWFRQVLVWHQWZLWKWKHHIIHFWLYHQHVVRIȕ-lactamȕ-lactamase 
inhibitor combinations against S. maltophilia strains, L2 is effectively inhibited by both 
avibactam and the bicyclic boronate 2. To investigate the molecular basis for inhibition of L2 
we crystallised the enzyme and soaked the crystals in avibactam or 2. Consistent with our 
inhibition kinetics results, we were unable to obtain crystal structures of complexes of L1 
with either of these inhibitors. L2 crystallised in the space group P212121 with two molecules 
in the asymmetric unit (Table S3), and closely conserves the overall SBL fold with, for 
example, an RMSD to KPC-2 (PDB 2OV5) of 0.2 Å. L2 crystals formed in a reagent 
containing a 0.1 M racemic mixture of the amino acids glutamate, alanine, lysine and serine. 
The active site manifests clear Fo-Fc density into which a molecule of D-glutamate could be 
modelled (Fig S4A), indicating the D-enantiomer preferentially binds to L2. However, 
binding does not perturb the active site conformation compared with an un-complexed L2 
crystal structure (PDB 1O7E) (Fig S5), preserving positioning of the hydrolytic (deacylating) 
water with respect to Glu166, Asn170 and Ser70 (see Table S4 for distances), and the 
conformation of the conserved, catalytically important Lys73 (Meroueh et al., 2005, Fonseca 
et al., 2012, Vandavasi et al., 2016). D-glutamate binds non-covalently, through interactions 
of its carbonyl oxygen with the backbone amides in the oxyanion hole (formed by residues 
Ser70 and Ser237), the C-terminal oxygen with Ser130-2Ȗ, and the glutamate amide with the 
deacylating water (Fig. 2A). Despite these extensive interactions, there is little inhibitory 
effect, with 100 mM D-glutamate reducing L2 activity by just 20% (Fig. S6), indicating 
binding is weak and the ligand can be easily displaced by substrate. The presence of D-
glutamate in the active site of our L2 crystal structure is therefore a crystallisation artefact 
and is due to the excess of amino acid in the crystallisation buffer. D-glutamate binds 
This article is protected by copyright. All rights reserved.
10 
 
differently compared with the high affinity binding (Ki = 84 pM) of the ȕ-lactamase 
inhibitory protein (BLIP) to the class A ȕ-lactamase KPC-2 (PDB 3E2K). Interestingly, BLIP 
binding to KPC-2 involves localisations of an L-aspartate residues at the active site, in a 
manner related to, but different from, D-glutamate binding to L2, and one that does not 
involve interactions with the oxyanion hole (Fig. S7) (Hanes et al., 2009). 
L2:avibactam and L2:bicyclic boronate 2 co-complex structures were solved to 
1.35 Å and 2.09 Å resolution, respectively, with clear Fo-Fc density indicating both inhibitors 
form a covalent attachment to the active site nucleophile Ser70 (Figs S4B and S4C). Binding 
by both compounds reveals no significant changes in the L2 active site in comparison with 
the apo or D-glutamate structures. Indeed, in both structures the deacylating water is 
positioned similarly to the native and D-glutamate-bound structures (Table S4).  
The bicyclic boronate 2 binds covalently to Ser70 of L2 (Figure 2B) with the boron 
atom clearly in a tetrahedral geometry. This is also observed previously on binding of the 
closely related bicyclic boronate 1 to CTX-M-15 (another class A ESBL) (Cahill et al., 2017) 
and OXA-10 (a class D SBL) (Brem et al., 2016). Hence, bicyclic boronates bind SBLs in a 
form that mimics the first tetrahedral intermediate formed GXULQJȕ-lactam hydrolysis, which 
is involved in acyl-enzyme formation, rather than mimicking the acyl-enzyme itself, i.e. these 
inhibitors are µWUDQVLWLRQVWDWHDQDORJXHs¶. As in D-glutamate binding, the assigned OH group 
on the boron atom is positioned to make strong interactions with the backbone amides of 
Ser70 (2.95 Å) and Ser237 (3.1 Å) in the oxyanion hole. The bicyclic boronate 2 makes 
additional hydrogen bonds to the side chains of the catalytically important residues Ser130 
(2.77 Å to the bicyclic ring oxygen), Asn132 (3.0 Å to the benzamide oxygen), Ser237 
(2.96 Å to the carboxylate) Thr235 (2.65 Å to the carboxylate), and the backbone carbonyl 
oxygen of Ser237 (3.1 Å to the benzamide nitrogen). In addition, binding is stabilised by 
significant hydrophobic interactions with His105.  
This article is protected by copyright. All rights reserved.
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Avibactam (Figure 2C) binds to L2 in its ring opened form, forming a carbamoyl-
enzyme complex (Ehmann et al., 2012) in which its six-membered ring is in a chair 
conformation, a conserved feature in other structurally characterised avibactam:ȕ-lactamase 
complexes (Krishnan et al., 2015, King et al., 2015, Lahiri et al., 2015, Xu et al., 2012, 
Lahiri et al., 2013, Lahiri et al., 2014). Highlighting the importance of the oxyanion hole, as 
with both D-glutamate and the bicyclic boronate 2, the avibactam derived carbamoyl oxygen 
is positioned to make hydrogen bonds with the oxyanion hole backbone amides of Ser70 
(2.75 Å) and Ser237 (2.85 Å). His105 is also involved in providing stabilising hydrophobic 
interactions (3.49 Å), while the carbamoyl NH interacts with the backbone carbonyl of 
Ser237 (3.08 Å) and the Asn132 sidechain (2.97 Å). The carbamoyl NH interactions may be 
relatively less important as they present in only one molecule in the asymmetric unit (chain 
B). The avibactam sulfate moiety interacts with the OH groups of both Thr235 (3.10 Å) and 
Ser130 (2.88 Å), with an additional 3.19 Å interaction with Ser237 in chain B.  
 
ȕ-Lactamase production is not induced by avibactam and the bicyclic boronate 2 
One important consideration when deploying ȕ-lactamase inhibitors into clinical practice is 
that some can interact with penicillin binding proteins and trigger ȕ-lactamase induction 
pathways carried by many bacteria. L1 and L2 production in S. maltophilia is controlled by a 
transcriptional regulator, AmpR, which is responsive to ȕ-lactam challenge via sensing ȕ-
lactam mediated perturbations in peptidoglycan breakdown and recycling (Jacobs et al., 
1997, Jacobs et al., 1994). Hence, we tested the ability of ȕ-lactamase inhibitors to induce E-
lactamase production in S. maltophilia. Clavulanic acid induces L1 production (measured 
using meropenem hydrolysis in cell extracts) at a similar level to the positive control ȕ-
lactam cefoxitin in the S. maltophilia wild type strain K279a (Fig. 3). This observation 
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rationalizes why clavulanic acid does not reduce the MIC of ceftazidime against S. 
maltophilia K279a (Table 2): induction of L1 (Fig. 3) overcomes inhibition of L2 (Table 3) 
because L1 can hydrolyse ceftazidime (Table 1). Since L1 does not hydrolyse aztreonam 
(Table 1), however, clavulanic acid reduces the aztreonam MIC against K279a, despite its 
ability to induce L1 production (Table 2, Fig. 3). Notably, by contrast with clavulanic acid, 
both avibactam and the bicyclic boronate 2 reduce ceftazidime MICs against K279a (Table 
2). This observation is explained by the important finding that neither avibactam nor 2 
induces L1 to any measurable extent (Fig. 3), yet both inhibit L2 (Table 3).  
 
Selection and characterisation of mutants which overcome the reversal of ceftazidime 
resistance by avibactam and the bicyclic boronate 2. 
Avibactam is currently only clinically available in combination with ceftazidime. The fact 
that L1 induction by clavulanic acid overcomes its ability to reduce ceftazidime MICs against 
S. maltophilia (Fig. 3, Table 2) led us to suggest that L1/L2 hyper-producing, ceftazidime 
resistant strains might further mutate to be ceftazidime resistant in the presence of avibactam 
and the bicyclic boronate 2 by producing even more L1. To investigate this possibility, we 
used a K279a ampR mutant, M11, which is ceftazidime resistant due to L1/L2 hyper-
production but where ceftazidime resistance can be reversed following treatment with 
avibactam or 2 at 10 mg.L-1 (Table 4). We aimed to identify mutants able to grow on 
ceftazidime at >32 mg.L-1 (i.e. clinically resistant, according to CLSI breakpoints (CLSI, 
2015) in the presence of either avibactam or 2 at 10 mg.L-1. Mutants were readily obtained; 
those selected using ceftazidime/avibactam were also resistant to ceftazidime/2, and vice 
versa (Table 4). To investigate the basis for resistance, LC-MS/MS proteomics was used to 
quantify changes in protein production in the two mutants. In both cases, L1 was produced at 
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levels ~3-fold greater than in the parent strain (Table S5, S5, Fig. 4A). This result was 
confirmed by measuring L1 enzyme activity in cell extracts using meropenem as substrate 
(Fig 4B). Thus, hyper-production of L1 can overcome the ability of these L2-specific 
inhibitors to rescue ceftazidime activity against a ceftazidime-resistant strain. Importantly, 
however, the mutants were still sensitive to the aztreonam/avibactam or aztreonam/2 
combinations (Table 4) as L1 cannot hydrolyse aztreonam (Table 1). The L1 hyper-
producing phenotype, blocking reversal of ceftazidime, but not aztreonam, resistance by ȕ-
lactamase inhibitors is clearly relevant, because it is displayed by clinical isolate CI-31 
(Table 2).  
 
DISCUSSION 
Our structural data reveal that the bicyclic boronate 2 binds to the ESBL L2 in a manner 
similar to that previously observed for the closely related bicyclic boronate 1 binding to the 
ESBL CTX-M-15. For the bicyclic boronate 2, binding of the tetrahedral boron atom to L2 
and conformation of the bicyclic fused core are all consistent with the CTX-M-15:bicyclic 
boronate 1 structure (Cahill et al., 2017); there is only slight variation in the 
amide/benzamide side chain conformations (Fig. 5A). Furthermore, formation of the L2 
carbamoyl-enzyme complex by avibactam results in a conformationally similar mode of 
binding compared with structurally-characterised complexes with the class A SBLs KPC-2 
(PDB 4ZBE) (Krishnan et al., 2015), SHV-1 (PDB 4ZAM) (Krishnan et al., 2015) and CTX-
M-15 (PDB 4S2I) (King et al., 2015) (Fig. 5B), and is consistent with data indicating 
avibactam to be similarly effective against these enzymes (Krishnan et al., 2015, Ehmann et 
al., 2012, Stachyra et al., 2009) However, some subtle differences in active-site interactions 
are observed (Fig S8). In particular, while the avibactam carbamoyl hydrogen bond with 
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Asn132 is conserved, the weaker carbamoyl interaction with the carbonyl oxygen of L2-
Ser237 is not, highlighting that such an interaction is not essential for binding. Furthermore, 
the avibactam sulfate moiety interaction with Thr235 is likely important as it presents in all 
SBLs, while interaction with Ser130 is present in KPC-2 alone. In SHV-1:avibactam, 
interaction of the sulfate group with the non-conserved Arg244 essentially substitutes for the 
sulfate-Ser237 interaction in other SBLs (Thr237 in KPC-2). In both SHV-1:avibactam and 
KPC-2:avibactam the µhydrolytic¶ Geacylating water molecule hydrogen bonds to the 
avibactam carbamoyl, while this interaction is not observed with either CTX-M-15:avibactam 
or L2:avibactam. The avibactam-derived sulfate-bonded nitrogen is in the same conformation 
as in KPC-2/SHV-1:avibactam and, unlike in the CTX-M-15:avibactam complex, is directed 
away from the six-membered ring and distant from Ser130 (Ser130, 3.57 Å) (King et al., 
2015) and consequently is not primed for re-cyclization (Choi et al., 2016) in which this 
residue is involved (Fig. 5B). The CTX-M-15:avibactam complex therefore remains to date 
as the only crystallographic evidence for avibactam reacting with an SBL in a conformation 
ideal for re-cyclization (King et al., 2015). Thus, the rate at which the avibactam derived 
complex can re-cyclize to reform intact avibactam may vary between SBLs.  
Even though our structural and kinetic work confirm that L2 is potently inhibited by 
avibactam and the bicyclic boronate 2, we predicted failure of avibactam/ceftazidime against 
S. maltophilia. Our prediction was based on the observation that L1-hyper-producing mutants 
are readily obtained from S. maltophilia isolates (Fig. 4), and avibactam does not inhibit 
MBLs (Abboud et al., 2016) . Whilst 2 inhibits subclass B1 MBLs (Brem et al., 2016) , our 
work reveals that it does not inhibit the subclass B3 MBL, L1 (Table 3, Fig S2) and so 
2/ceftazidime was also overcome by L1 hyper-production (Table 4, Fig. 4). It may be 
possible to modify 2 and so generate a broader-spectrum MBL inhibitor. However, a key 
finding of this work is that such a modification might not be essential. Avibactam and 2 both 
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facilitate killing of S. maltophilia when paired with the monobactam, aztreonam, reducing 
MICs to  4 mg.L-1 even in the pan-resistant clinical S. maltophilia isolate, CI-31 (Table 2). 
These data imply that aztreonam/avibactam and aztreonam/2 may have a promising clinical 
future for treatment of infections caused by this most intractable of species. The fact that 
efflux pump over-production does not affect aztreonam/2 or aztreonam/avibactam activity 
(Table 2) gives even greater cause for optimism. We were interested to read, therefore, a 
recent clinical case report demonstrating the use of combination therapy with 
ceftazidime/avibactam plus aztreonam to save the life of a patient with an S. maltophilia 
infection that had failed all prior therapy (Mojica et al., 2016). Our structural, kinetic and 
whole bacterial killing data would lead to the conclusion that ceftazidime was probably 
superfluous in this success, but our work indicates that ceftazidime/avibactam plus aztreonam 
might be routinely considered in the clinic for use against seemingly untreatable S. 
maltophilia infections whilst aztreonam/avibactam works its way through the clinical trials 
system. Positive results have been seen with ceftazidime/avibactam plus aztreonam against 
Enterobacteriaceae isolates carrying multiple ȕ-lactamases, but the combination was not 
universally efficacious (Marshall et al., 2017). 
In many respects, because of its inability to inhibit L1, the bicyclic boronate 2 acts 
against S. maltophilia very similarly to avibactam. One potentially significant difference is 
that avibactam is hydrolysed by L1, but 2 retains its structural integrity (Fig. S3). This 
hydrolysis is slow, and even if L1 is hyper-produced, it is not significant enough to confer 
aztreonam/avibactam resistance (Table 4). However, there is a chance that L1 mutants might 
be selected with greater avibactam hydrolytic activity, reducing the degree of L2 inhibition 
and raising the MIC of aztreonam/avibactam into the resistant range. This observation may 
also be of relevance to other avibactam-like compounds in development, e.g. Relebactam 
(Blizzard et al., 2014). In contrast, given that modification of 2 in the presence of wild-type 
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L1 is undetectably slow, evolution to increased breakdown may require significantly more 
steps, potentially increasing the long-term efficacy of aztreonam/2 as a combination to treat 
S. maltophilia infections. 
In conclusion, our combined results reveal the potential of non-classical non ȕ-lactam 
containing ȕ-lactamase inhibitors, including the clinically approved compound avibactam, 
and the cyclic boronates (some of which are presently in clinical trials) for treatment of S. 
maltophilia, particularly when partnered with the monobactam aztreonam, and perhaps other 
aztreonam-like ȕ-lactams currently in development. Given the structural differences between 
avibactam, cyclic boronates, and the ȕ-lactam based inhibitors, it would seem that there is 
considerable scope for the identification of new types of ȕ-lactamase inhibitors of potential 
clinical utility against Gram-negative bacterial pathogens. 
 
EXPERIMENTAL PROCEDURES 
Bacterial isolates and materials 
S. maltophilia clinical isolates were K279a, a well characterised isolate from Bristol, UK, or 
were obtained from the SENTRY antimicrobial resistance survey, as previously reported 
(Gould et al., 2006). 7KHFHIWD]LGLPHUHVLVWDQWȕ-lactamase hyper-producing K279a-derived 
mutants used were K CAZ 10 (Talfan et al., 2013) and K M11 (Okazaki & Avison, 2008). 
Efflux-pump over-producing mutants K AMI 32 and K MOX 8 were selected using K279a as 
parent strain as previously described (Gould & Avison, 2006). All growth media were from 
Oxoid. Chemicals were from Sigma, unless otherwise stated. Avibactam was from 
AstraZeneca whilst cyclic boronate 2 was synthesised according to published protocols 
(Burns et al., 2010). 
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$VVD\ RI ȕ-lactamase activity in cell extracts, ȕ-ODFWDPDVH LQGXFWLRQ DQG ȕ-lactam 
susceptibility 
Cultures were grown overnight using nutrient broth and used to inoculate (1:100 dilution) 10 
mL nutrient broth cultures in sealed 30 mL universal bottles. Cultures were incubated for 2 h 
with shaking at 37°C before test inducers were added, or not, and culture was continued for 2 
h. Cells were pelleted by centrifugation (4,000 x g, 10 min) and pellets treated with 100 µL of 
BugBuster (Ambion), pipetting up and down a few times before rocking for 10 min at room 
temperature. Cell debris and unlysed cells were pelleted by centrifugation (13,000 x g, 5 min) 
and the supernatant retained as a source of crude cell protein. Protein concentrations were 
determined using the BioRad protein assay reagent concentrate according to the 
PDQXIDFWXUHU¶V LQVWUXFWLRQV / ȕ-lactamase activity was determined using an Omega 
Fluostar (BMG Biotech) using meropenem as substrate in half-area 96 well UV-translucent 
plates (Greiner UV-Star. Bio-one) with 200 µL of 100 µM meropenem solution in assay 
buffer (60 mM Na2HPO4·7H2O pH 7.0, 40 mM NaH2PO4·H2O, 10 mM KCl, 1 mM 
MgSO4·7H2O, 100 µM ZnCl2) plus 10 µL of cell extract. Substrate depletion was followed at 
300 nm for 10 mins and an extinction coefficient of 9600 AU.M-1.cm-1 was used to calculate 
enzyme activity in the linear phase of the reaction.  
6XVFHSWLELOLW\ WR ȕ-lactams in bacterial isolates was determined using the CLSI 
microtitre MIC methodology with Muller-Hinton Broth using 96 well plates (Corning, 
Costar). The MIC ZDVGHWHUPLQHGDVWKHORZHVWFRQFHQWUDWLRQRIȕ-lactam required to entirely 
suppress growth (CLSI, 2015). Inhibitor concentrations were kept constant at 2 mg.L-1 or 10 
mg.L-1 in all assays. Interpretation of susceptibility/resistance was by reference to CLSI 
clinical breakpoints for S. maltophilia (ceftazidime) and for Pseudomonas aeruginosa (for 
aztreonam and meropenem, since no S. maltophilia breakpoints are available) (CLSI, 2015). 
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Proteomic Analysis 
Cells in 50 mL nutrient broth cultures were pelleted by centrifugation (10 min, 4,000 × g, 
Û&DQGUHVXVSHQGHGLQP/RIP07ULV-HCl, pH 8 and broken by sonication using a 
cycle of 1 sec on, 0.5 sec off for 3 min at amplitude of 63% using a Sonics Vibracell VC-
505TM (Sonics and Materials Inc., Newton, Connecticut, USA). The sonicated samples were 
centrifuged at 8,000 rpm (Sorval RC5B PLUS using an SS- URWRU IRU  PLQ DW Û& WR
pellet intact cells and large cell debris; the supernatant was removed and concentrated 
(Amicon 3 kDa cutoff filter) for analysis of total cell protein. Alternatively, for envelope 
preparations, the supernatant was not concentrated, and instead, subjected to centrifugation at 
USPIRUPLQDWÛ&XVLQJWKHDERYHURWRUWRSHOOHWWRWDOHQYHORSHV7RLVRODWHWRWDO
HQYHORSHSURWHLQVWKLVWRWDOHQYHORSHSHOOHWZDVVROXELOLVHGXVLQJȝ/RIP07ULV-HCl 
pH 8 containing 0.5% (w/v) SDS.  
Protein concentrations in all samples was quantified using Biorad Protein Assay Dye Reagent 
&RQFHQWUDWHDFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV3URWHLQV2.5 ȝJ/Lane for total cell 
proteomics or 5 µg/Lane for envelope protein analysis) were separated by SDS-PAGE using 
11% acrylamide, 0.5% bis-acrylamide (Biorad) gels and a Biorad Min-Protein Tetracell 
chamber model 3000X1. Gels were resolved at 200 V until the dye front had moved 
approximately 1 cm into the separating gel. Proteins in all gels were stained with Instant Blue 
(Expedeon) for 20 min and de-stained in water.  
The 1 cm of gel lane was subjected to in-gel tryptic digestion using a DigestPro 
automated digestion unit (Intavis Ltd).  The resulting peptides from each gel fragment were 
fractionated separately using an Ultimate 3000 nanoHPLC system in line with an LTQ-
Orbitrap Velos mass spectrometer (Thermo Scientific). In brief, peptides in 1% (v/v) formic 
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acid were injected onto an Acclaim PepMap C18 nano-trap column (Thermo Scientific). 
After washing with 0.5% (v/v) acetonitrile plus 0.1% (v/v) formic acid, peptides were 
UHVROYHG RQ D  PP î  ȝP $FFODLP 3HS0DS & UHYHUVH SKDVH DQDO\WLFDO FROXPQ
(Thermo Scientific) over a 150 min organic gradient, using 7 gradient segments (1-6% 
solvent B over 1 min., 6-15% B over 58 min., 15-32% B over 58 min., 32-40% B over 5 
min., 40-90% B over 1 min., held at 90% B for 6 min and then reduced to 1% B over 1 min.) 
with a flow rate of 300 nL/min.  Solvent A was 0.1% formic acid and Solvent B was aqueous 
80% acetonitrile in 0.1% formic acid. Peptides were ionized by nano-electrospray ionization 
MS at 2.1 kV using a stainless-steel HPLWWHU ZLWK DQ LQWHUQDO GLDPHWHU RI  ȝP 7KHUPR
Scientific) and a capillary temperature of 250°C. Tandem mass spectra were acquired using 
an LTQ-Orbitrap Velos mass spectrometer controlled by Xcalibur 2.1 software (Thermo 
Scientific) and operated in data-dependent acquisition mode. The Orbitrap was set to analyze 
the survey scans at 60,000 resolution (at m/z 400) in the mass range m/z 300 to 2000 and the 
top twenty multiply charged ions in each duty cycle selected for MS/MS in the LTQ linear 
ion trap. Charge state filtering, where unassigned precursor ions were not selected for 
fragmentation, and dynamic exclusion (repeat count, 1; repeat duration, 30 s; exclusion list 
size, 500) were used. Fragmentation conditions in the LTQ were as follows: normalized 
collision energy, 40%; activation q, 0.25; activation time 10 ms; and minimum ion selection 
intensity, 500 counts. 
The raw data files were processed and quantified using Proteome Discoverer software 
v1.4 (Thermo Scientific) and searched against the UniProt S. maltophilia strain K279a 
database (4365 protein entries; UniProt accession UP000008840) using the SEQUEST (Ver. 
28 Rev. 13) algorithm. Peptide precursor mass tolerance was set at 10 ppm, and MS/MS 
tolerance was set at 0.8 Da. Search criteria included carbamidomethylation of cysteine 
(+57.0214) as a fixed modification and oxidation of methionine (+15.9949) as a variable 
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modification. Searches were performed with full tryptic digestion and a maximum of 1 
missed cleavage was allowed. The reverse database search option was enabled and all peptide 
data was filtered to satisfy false discovery rate (FDR) of 5 %. The Proteome Discoverer 
VRIWZDUHJHQHUDWHVD UHYHUVH³GHFR\´GDWDEDVH IURPWKHVDPHSURWHLQGDWDEDVHXVHG IRU WKH
analysis and any peptides passing the initial filtering parameters that were derived from this 
decoy database are defined as false positive identifications. The minimum cross-correlation 
factor filter was readjusted for each individual charge state separately to optimally meet the 
predetermined target FDR of 5 % based on the number of random false positive matches 
from the reverse decoy database. Thus, each data set has its own passing parameters. Protein 
abundance measurements were calculated from peptide peak areas using the Top 3 method 
(Silva et al., 2006) and proteins with fewer than three peptides identified were excluded. The 
proteomic analysis was repeated three times for each parent and mutant strain, each using a 
separate batch of cells. Data analysis was as follows: all raw protein abundance data were 
uploaded into Microsoft Excel. Raw data from each sample were normalised by division by 
the average abundance of all 30S and 50S ribosomal protein in that sample. A one-tailed, 
unpaired T-test was used to calculate the significance of any difference in normalised protein 
abundance data in the three sets of data from the parent strains versus the three sets of data 
from the mutant derivative. A p-value of <0.05 was considered significant. The fold change 
in abundance for each protein in the mutant compared to its parent was calculated using the 
averages of normalised protein abundance data for the three biological replicates for each 
strain. All raw protein abundance data are provided in the attached proteomics data file. 
 
Purification of L1 and L2 and kinetics assays 
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Recombinant L1 and L2 proteins were produced in E. coli and purified as previously 
described (Calvopina et al., 2016). Enzyme activity was monitored using an Omega 
Fluostar (BMG Labtech) using buffer L1 (50 mM HEPES pH 7.5, 10 µg.mL-1 BSA, 10 
µM ZnSO4 and 0.01% v/v Triton X-100) and buffer L2 (50 mM Tris pH 7.5, 10 µg.mL-1 
BSA and 0.01% v/v Triton X-100). Reactions were carried out as described in (van Berkel 
et al., 2013). For the chromogenic substrates meropenem, ceftazidime and aztreonam, 
substrate depletion was measured at 300 nm, 260 nm, 318 nm, respectively whilst for the 
fluorogenic substrate FC5, the excitation wavelength was set at 380nm and emission 
wavelength at 460 nm (van Berkel et al., 2013). Clavulanic acid was dissolved in double 
distilled water while avibactam and the bicyclic boronate 2 were dissolved in DMSO to 
prepare an appropriate stock solution. IC50 values were calculated from reactions using 
FC5 (50 nM) as substrate for both L1 and L2 (used at 50 pM). Steady state kinetic data 
were analysed by curve fitting to the Michaelis-Menten equation using Prism software.  
 
L2 Crystallisation, Data Collection and Structure Modelling 
Initial L2 crystals grew using sitting-drop vapour diffusion in 96-well MRC 2-drop plates 
(Molecular Dimensions) with the Morpheus sparse matrix screen (Gorrec, 2009). Conditions 
were refined in CrysChem 24-well sitting-drop plates (Hampton Research, 18 °C), and 
diffraction-quality crystals were obtained by mixing 1 µL of L2 protein (42 mg.mL-1) with 
1.5 µL reagent (10% w/v PEG 20000, 20% v/v PEG MME 550, 0.02 M DL-Glutamic acid; 
0.02 M DL-Alanine; 0.02 M Glycine; 0.02 M DL-Lysine; 0.02 M DL-Serine, 0.1 M 
bicine/Trizma base pH 8.5) and equilibrated against 500 µL reagent. L2 complexes were 
obtained by soaking crystals in bicyclic boronate 2 (5 min, 2.5 mM) or avibactam (40 min, 
5 mM) dissolved in reservoir reagent. L2 crystals were cryoprotected using reservoir solution 
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plus 20% glycerol and flash frozen in liquid nitrogen. Crystallographic data were collected at 
100K (I04-1, I04 or I03, Diamond Light Source, UK) and integrated in XDS (Kabsch, 2010) 
or DIALS (Waterman et al., 2016), and scaled in Aimless in the CCP4 suite (Winn et al., 
2011). Phases were calculated by molecular replacement in Phaser (McCoy et al., 2007) 
using PDB 1O7E (unpublished) as a starting model. Avibactam and boronate structures, 
covalently bound to Ser70, and geometric restraints were generated using Phenix eLBOW 
(Moriarty et al., 2009). Structures were completed by iterative rounds of manual model 
building in Coot (Emsley et al., 2010) and refinement in Phenix (Adams et al., 2010). 
Structure validation was assisted by Molprobity (Chen et al., 2010) and Phenix (Adams et al., 
2010). Figures were prepared using Pymol (Schrodinger).   
 
NMR Spectroscopy 
The potential impact of avibactam or the bicyclic boronate 2 (both 75 PM) on the hydrolysis 
of meropenem (1 mM) by L1 (75 nM) was monitored over 20 min. The hydrolysis of 
avibactam (400 PM) and 2 (400 PM) by L1 (10 PM) was monitored over the course of 18 h 
or 24 h, respectively. All substrates, inhibitors, and enzymes were prepared in 50 mM Tris-
d11, pH 7.5, 10 % D2O. Spectra were acquired on a Bruker AVIII 700 MHz spectrometer 
equipped with a 1H/13C/15N TCI cryoprobe, and a Bruker AVIIIHD 600 MHz spectrometer 
equipped with a Prodigy broadband cryoprobe. 1H spectra were acquired at 298 K using a 2 s 
relaxation delay, and were processed with a 0.3 Hz line broadening. The water signal was 
suppressed by excitation sculpting with perfect echo. 
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TABLES  
 
7DEOH.LQHWLFGDWDIRUȕ-lactams tested against metallo L1 and serine L2 S. 
maltophilia ȕ-lactamases. 
Enzyme Substrate [E] (µM) KM (µM) kcat (s-1) kcat/KM 
(M-1.s-1) x10-9 
L1 Ceftazidime 0.5 260 1.7 6.5 
 
Aztreonam 0.5 - - - 
 
Meropenem 0.01 110 24 220 
 
FC5 0.05 30 150 5,000 
L2 Ceftazidime 0.5 550 1.9 3.5 
 
Aztreonam 0.5 120 0.08 0.67 
 
Meropenem 0.625 29 0.03 1.0 
 
FC5 0.05 18 210 12,000  
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Table 2. Minimum Inhibitory Concentrations (mg.L-1) of ȕ-lactams against S. 
maltophilia in the presence of ȕ-lactamase inhibitors used at 2 mg.L-1. 
 Ceftazidime Aztreonam Meropenem 
 - +CLA +BOR +AVI - +CLA +BOR +AVI - +CLA +BOR +AVI 
K279a 4 4 0.5 1 128 1 1 1 8 32 4 16 
CI-20 16 16 2 4 128 4 2 2 64 32 8 64 
CI-29 8 4 0.5 1 128 1 1 1 32 16 8 32 
K CAZ 10 64 8 4 8 256 0.5 1 1 64 8 16 64 
CI-31 256 128 128 128 256 2 4 4 256 256 256 256 
K AMI 32 2 1 1 0.5 128 0.5 1 0.5 4 8 4 16 
K MOX 8 4 1 0.5 0.5 128 0.25 1 0.5 4 8 8 16 
 
Shaded values indicate clinically relevant resistance according to CLSI breakpoints (CLSI, 
2015) 
CLA, clavulanic acid; BOR, bicyclic boronate 2; AVI, avibactam 
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Table 3. Inhibition of L2 by ȕ-lactamase inhibitors in vitro. 
 
Inhibitor IC50 (nM) pIC50 
Clavulanic Acid 22.3 7.41 
Avibactam 14.36 7.84 
Bicyclic Boronate 2 5.25 8.27 
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Table 4 MICs (mg.L-1) of ȕ-lactams against S. maltophilia mutants in the presence of ȕ-
lactamase inhibitor (10 mg.L-1). 
 
 
 
  
Ceftazidime Aztreonam 
- +BOR +AVI - +BOR +AVI 
K279a 4 0.5 1 128 1 1 
M11 128 8 2 256 1 1 
MA27 256 32 32 256 4 4 
MB25 256 64 128 256 4 4 
 
Shaded values represent resistance according to CLSI breakpoints. 
BOR, bicyclic boronate 2; AVI, avibactam. 
MA27 and MB25 were selected for growth at 32 mg.L-1 ceftazidime in the presence of 10 
mg.L-1 avibactam or bicyclic boronate 2, respectively using M11 as parent strain. M11 is an 
L1/L2 hyper-producing mutant derived from K279a, which is wild-type [37]. 
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FIGURE LEGENDS 
 
)LJXUH&KHPLFDOVWUXFWXUHVRIȕ-lactamase inhibitors.  
Top, clavulanic acid. Middle, avibactam and the acyl-enzyme complex formed on the 
(potentially reversible) reaction of avibactam with 6HULQHȕ-lactamases. Bottom, left: the 
monocyclic boronate, vaborbactam; right: bicyclic boronate 2.  
 
Figure 2. ,QWHUDFWLRQRIȕ-lactamase inhibitors with the L2 active site. 
View of L2 (shown in green cartoon) active sites with bound ligands (blue sticks), (A) D-
glutamate, (B) bicyclic boronate 2 and (C) avibactam. Interactions between residues and the 
catalytic water are shown as red dashes, and interactions between residues and ligand as blue 
dashes. Labelled residues are those that specifically interact with the ligand. 
 
Figure 3. /ȕ-ODFWDPDVHLQGXFWLRQE\ȕ-lactamase inhibitors in S. maltophilia K279a.  
S. maltophilia isolate K279a was incubated in presence of different potential inducers 
(cefoxitin, clavulanic acid, the bicyclic boronate 2, or avibactam) at 50 mg.L-1). L1 activity 
was measured from the cell extracts in a 96-well plate reader by determining meropenem 
hydrolysis (100 0 DW Ȝ 300 nm. Protein concentration was determined by using the 
BioRad protein assay dye reagent. Specific activity was calculated by using the extinction 
coefficient of 9600 AU.M-1.cm-1 and a pathlength correction for the microplate (0.62 cm). 
Data presented are means +/- SEM, n=3. 
 
Figure 4. L1 activity of inhibitor resistant mutants  
In (A), L1 protein abundance data (relative to mean ribosomal protein abundance for each 
sample). Full proteomics data are shown in Tables S5 and S6. In (B), L1 enzyme activity in 
cell extracts is reported as meropenem hydrolysis rate. Data are reported as mean +/- SEM, 
n=3 for the parent strain, M11, and the two mutants (MB25 and MA27), which are resistant 
to ceftazidime/avibactam and ceftazidime/2.   
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Figure 5. Bicyclic boronate DQGDYLEDFWDPELQGLQJFRQIRUPDWLRQVLQ&ODVV$ȕ-
lactamases.  
Superposition of inhibitors, shown as sticks, bound in the active sites of Class A ȕ-
lactamases. (A) Bicyclic boronates bound to L2 (blue, bicyclic boronate 2) and CTX-M-15 
(grey, bicyclic boronate 1). (B) Avibactam bound to L2 (blue), SHV-1 (grey), KPC-2 (green) 
and CTX-M-15 (orange). Note the common binding mode for the bicyclic boronate bicyclic 
core and most of the avibactam structure; there are differences in the orientations of the 
avibactam core derived nitrogen (see text).   
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ABBREVIATED SUMMARY 
	
 	

 is an important bacterial pathogen that causes severe 
infections. It can become resistant to all β"lactam antibacterials via mutations that 
enhance L1 and L2 β"lactamase production. Characterisation of the interactions 
between various β"lactamase inhibitors and L1 and L2, whole cell susceptibility tests 
and proteomic analysis of resistant mutants show that the monobactam aztreonam plus 
the non"β"lactam based β"lactamase inhibitors avibactam and a novel cyclic boronate 
are excellent combinations against 	

 
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